LeMaitre Vascular's (LMAT) Outperform Rating Reaffirmed at Barrington Research

Key Points

• Barrington Research has reaffirmed an "outperform" rating for LeMaitre Vascular (NASDAQ:LMAT) with a target price of $95.00, indicating an 8.72% potential upside from its previous close.
• The company's recent earnings report showed a 15% year-over-year revenue increase and earnings per share (EPS) of $0.60, exceeding analysts' estimates.
• Insiders have significantly sold shares recently, with over 120,000 shares valued at $11.28 million sold in the last three months.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Barrington Research in a research report issued on Wednesday,Benzinga reports. They currently have a $95.00 target price on the medical instruments supplier's stock. Barrington Research's price target would suggest a potential upside of 8.72% from the stock's previous close.

Several other brokerages also recently weighed in on LMAT. Weiss Ratings restated a "buy (b-)" rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Cantor Fitzgerald raised their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $97.60.

LeMaitre Vascular Trading Up 2.4%

NASDAQ LMAT opened at $87.38 on Wednesday. The company has a 50 day moving average price of $92.24 and a 200 day moving average price of $86.40. The firm has a market cap of $1.98 billion, a PE ratio of 42.42, a price-to-earnings-growth ratio of 2.20 and a beta of 0.77. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business's revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 10,815 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This represents a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bridget A. Ross sold 2,500 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. This represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by insiders.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in shares of LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock valued at $9,385,000 after buying an additional 3,248 shares during the period. US Bancorp DE boosted its stake in LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 368 shares during the period. Johnson Investment Counsel Inc. lifted its stake in LeMaitre Vascular by 34.8% during the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock worth $2,469,000 after purchasing an additional 7,603 shares during the last quarter. Consolidated Planning Corp bought a new stake in shares of LeMaitre Vascular in the 1st quarter valued at about $947,000. Finally, Northern Trust Corp grew its holdings in shares of LeMaitre Vascular by 5.4% during the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier's stock worth $28,993,000 after acquiring an additional 17,748 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.